This compound is primarily utilized in the development of antibody-drug conjugates (ADCs) for targeted cancer therapy. It serves as a potent cytotoxic agent, specifically designed to be linked to monoclonal antibodies that selectively target cancer cells. Once the ADC binds to the target cell, the compound is released intracellularly, where it inhibits microtubule assembly, leading to cell cycle arrest and apoptosis. Its high potency makes it particularly effective in treating cancers with low antigen expression. Additionally, its stability and controlled release mechanism enhance the therapeutic window, minimizing off-target effects and improving patient outcomes in clinical oncology.